Orthofix International announced the full market release of Collage Osteoconductive Scaffold, a new bone graft substitute, for use in spine and orthopaedic indications, at the North American Spine Society (NASS) meeting in Chicago, USA.
“We are proud to announce the launch of Collage, our new synthetic platform based on highly-purified biocompatible materials of ß-TCP and type-1 collagen,” said Michael Finegan, Orthofix’s president of Biologics. “We have been tremendously successful with Trinity Evolution and can now focus on broadening our portfolio of biologic products so that we can fulfill all the needs of our customers. The synthetic segment of the market is large, attractive, and presents a perfect complement to our existing biologic portfolio.”
The US market for synthetic bone graft substitutes is estimated to include more than 320,000 procedures and is valued at approximately US$360 million annually, according to a recent iData Research report.
